The US Food and Drug Administration (FDA) has instructed all GLP-1 drug-makers to update their warning labels to include the ...

Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are associated with reduced type 2 diabetes mellitus (T2DM)-related ...

Stopping anti-obesity medications leads to significant weight regain, starting as early as eight weeks and stabilizing by six ...

People who stop taking GLP-1 medications like Ozempic and Wegovy started to regain weight in a short amount of time, ...

The U.S. Food & Drug Administration (FDA) has approved certain GLP-1 drugs for commercialization and use, including liraglutide ...

For adults with type 2 diabetes and obesity, glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are associated with a lower risk for dementia, stroke, and all-cause mortality compared with other ...

The hormonal changes of menopause can make the weight gain more resistant to traditional diet and lifestyle changes. But GLP-1s can be an effective reinforcement of diet and exercise.